Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Tim Illidge

The University of Manchester

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Immunology

70%

Epidemiology

20%

Cancer Biology

60%

Radiation Therapy

30%

Oncology

30%

Lymphoma

30%

Graft-versus-host Disease

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles15

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study

Article Link

Year:

2025

The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline

Article Link

Year:

2024

Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer

Article Link

Year:

2023

Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials

Article Link

Year:

2023

A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Article Link

Year:

2023

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies

Article Link

Year:

2023

IRF7 impacts on prostate cancer cell survival in response to radiation

Article Link

Year:

2022

Immunomodulation by radiotherapy in tumour control and normal tissue toxicity

Article Link

Year:

2022

Low CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer

Article Link

Year:

2022

Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer

Article Link

Year:

2022

Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline

Article Link

Year:

2021

The ECHELON-2 Trial

Article Link

Year:

2021

Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries

Article Link

Year:

2021

The effect of hypoxia on PD-L1 expression in bladder cancer

Article Link

Year:

2021

Progress and pitfalls with the use of image-guided personalised approaches in lymphoma

Article Link

Year:

2021

Collaborators15

Mick Brown

The University of Manchester

UNITED KINGDOM

Mark Travis

Professor of Immunology

University of Manchester

UNITED KINGDOM

Sally Barrington

King’s College London

UNITED KINGDOM

Debayan Mukherjee

The University of Manchester

UNITED KINGDOM

Claire Alexandra Hart

The University of Manchester

UNITED KINGDOM

Peter Hoskin

The University of Manchester

UNITED KINGDOM

Hitesh Mistry

The University of Manchester

UNITED KINGDOM

Douglas Dyer

The University of Manchester

UNITED KINGDOM

Graham McIlroy

NIHR Academic Clinical Lecturer in Haematology

University of Birmingham

UNITED KINGDOM

Elizabeth Phillips

The University of Manchester

UNITED KINGDOM

Urszula Cytlak

The University of Manchester

UNITED KINGDOM

Andrea Kuhnl

King's College Hospital

UNITED KINGDOM

Lucy Cook

Honorary Senior Clinical Lecturer

Imperial College London

UNITED KINGDOM

Christopher Paul Fox

Clinical Professor of Haematology

University of Nottingham

UNITED KINGDOM

Catharine West

The University of Manchester

UNITED KINGDOM

How do I reach out?

Meet Kite AI